Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Monoclonal anti-D immunoglobulin
- Development stage
- Preclinical
- Lead developer
- Bharat Serums and Vaccines
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
Monoclonal anti-D immunoglobulin is a laboratory-produced antibody that specifically targets the RhD antigen on red blood cells. It is designed to prevent RhD isoimmunization in Rh-negative individuals exposed to Rh-positive blood, such as during pregnancy or transfusion, and may also be used in the treatment of immune thrombocytopenic purpura (ITP) in Rh-positive patients. Unlike traditional polyclonal preparations derived from human plasma, monoclonal versions are produced using cell lines and offer a consistent supply with defined specificity. The mechanism of action involves binding to the RhD antigen on red blood cells, leading to their clearance and preventing an immune response against them[1][2][4][5]. Monoclonal products are under development or evaluation for these indications.
- Other names
- Monoclonal anti-d IgGMonoclonal anti-D antibody
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on Monoclonal anti-D immunoglobulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Monoclonal anti-D immunoglobulin.